Silver nanoparticle/capecitabine for breast cancer cell treatment

Basit Öğe Kaydı
dc.authoridEbru Nur Ay / 0000-0001-7121-4362en_US
dc.authorscopusidEbru Nur Ay / 57209852424
dc.authorwosidEbru Nur Ay / L-5910-2018
dc.contributor.authorHepokur, Ceylan
dc.contributor.authorKariper, İshak Afşin
dc.contributor.authorMısır, Sema
dc.contributor.authorAy, Ebru Nur
dc.contributor.authorTunoğlu, Servet
dc.contributor.authorErsez, Mediha Süleymanoğlu
dc.contributor.authorZeybek, Ümit
dc.contributor.authorKuruca, Serap Erdem
dc.contributor.authorYaylım, İlhan
dc.date.accessioned2020-08-30T20:06:26Z
dc.date.available2020-08-30T20:06:26Z
dc.date.issued2019
dc.departmentİstinye Üniversitesi, Sağlık Hizmetleri Meslek Yüksekokulu, Tıbbi Laboratuvar Teknikleri Bölümüen_US
dc.description.abstractThis study aimed to evaluate antiproliferative and proapoptotic effects of Capecitabine bonded silver particles on human breast cancer cells (MCF-7). Different sizes of Ag NPs (in sizes 5, 10, 15, 30 nm) were synthesized. The characterization of silver and drug-bonded silver nanoparticles was performed through UV-VIS, FTIR, and SEM analysis. Silver and drug-bonded silver nanoparticles were measured by zetasizer. Antiproliferative and proapoptotic effects of capecitabine, silver and drug-bonded silver nanoparticles were evaluated using XTT, Anneksin V, respectively. According to the results, silver nanoparticles of 10 nm size have shown the lowest toxic effect. Drug-bonded nanoparticles significantly increased the number of early and late apoptotic cells on MCF-7 cells.en_US
dc.identifier.citationHepokur, C., Kariper, I. A., Misir, S., Ay, E., Tunoglu, S., Ersez, M. S., … Yaylim, I. (2019). Silver nanoparticle/capecitabine for breast cancer cell treatment. TOXICOLOGY IN VITRO, 61. https://doi.org/10.1016/j.tiv.2019.104600en_US
dc.identifier.doi10.1016/j.tiv.2019.104600en_US
dc.identifier.issn0887-2333en_US
dc.identifier.pmid31302208en_US
dc.identifier.scopus2-s2.0-85068898097en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1016/j.tiv.2019.104600
dc.identifier.urihttps://hdl.handle.net/20.500.12713/514
dc.identifier.volume61en_US
dc.identifier.wosWOS:000497251800044en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorAy, Ebru Nuren_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofToxicology In Vitroen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBreast Cancer (Mcf-7)en_US
dc.subjectCapecitabineen_US
dc.subjectSilver Nanoparticlesen_US
dc.subjectApoptosisen_US
dc.titleSilver nanoparticle/capecitabine for breast cancer cell treatmenten_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
263.pdf
Boyut:
3.09 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıbbi Laboratuvar Teknikleri Programı Makale Koleksiyonu